% Expired Patents = 25.0

Forward Citations = 38

Loading Chart...

5 inventors (with patents filed for the assignee):

Edgar George Engleman (4 out of 46 patents)

C Garrison Fathman (4 out of 12 patents)

Erik Kreider (4 out of 4 patents)

4. Jonathan B Rothbard (4 out of 22 patents)

5. Paul Leo McGrane (4 out of 9 patents)

4 patents: Sort by Forward Citations

1. 9220744 - Compositions and methods for treating diseases (2015-12-29),

2. 8629115 - Compositions and methods for treating diseases (2014-01-14),

3. 7820626 - Compositions and methods for treating diseases (2010-10-26),

4. 7557087 - Compositions and methods for treating diseases (2009-07-07),

Company Overview

Lumen Therapeutics, LLC is a leading biotechnology company focused on developing innovative treatments for various diseases and medical conditions. With a team of dedicated researchers and scientists, Lumen Therapeutics is committed to advancing the field of healthcare through cutting-edge research and development. Their mission is to improve the lives of patients by delivering effective and safe therapies. Visit their website to learn more about their latest projects and breakthroughs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

4 Patents

#241 in Menlo Park, CA

#14,041 in California

#60,597 in US

Menlo Park, CA, United States of America

Lumen Therapeutics, LLC

Forward Citations = 38

5 inventors:

Edgar George Engleman (4 out of 46 patents)

C Garrison Fathman (4 out of 12 patents)

Erik Kreider (4 out of 4 patents)

4. Jonathan B Rothbard (4 out of 22 patents)

5. Paul Leo McGrane (4 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lumen Therapeutics, LLC. Retrieved from https://idiyas.com/company/lumen-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]